FDA approves Gilead’s Veklury for COVID-19 patients with severe renal impairment
Gilead Sciences said that the US Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for Veklury (remdesivir) usage in COVID-19 ... Read More
Gilead Sciences gets Veklury FDA approval for non-hospitalized Covid-19 patients
Gilead Sciences has secured expedited approval from the US Food and Drug Administration (FDA) for its nucleotide analog Veklury (remdesivir) for the treatment of non-hospitalized ... Read More
Natco Pharma signs licensing deal with Lilly for Covid drug Baricitinib
Natco Pharma has signed a royalty-free, non-exclusive, voluntary licensing agreement with Eli Lilly and Company (Lilly) for manufacturing and commercializing Baricitinib for the treatment of ... Read More
Torrent Pharma signs licensing deal with Lilly for Covid drug baricitinib
Torrent Pharmaceuticals (Torrent Pharma) has signed a licensing agreement with Eli Lilly and Company with an objective to bring the latter’s baricitinib for Covid-19 treatment ... Read More
Dr. Reddy’s Laboratories, Lilly sign deal for Covid-19 drug baricitinib
Dr. Reddy’s Laboratories said that it has forged a royalty-free, non-exclusive voluntary licensing agreement with US pharma giant Eli Lilly and Company (Lilly) for the ... Read More
Sun Pharma signs licensing deal with Lilly for Covid-19 drug baricitinib
Sun Pharmaceutical Industries (Sun Pharma) said that it has signed a royalty-free, non-exclusive voluntary licensing agreement with Eli Lilly and Company for expanding access to ... Read More
Lupin strikes deal with Lilly for Covid-19 drug Baricitinib in India
Lupin Limited said that it has signed a royalty-free, limited, non-exclusive voluntary licensing agreement with Eli Lilly and Company (Lilly) for manufacturing and selling the ... Read More
Natco Pharma gets CDSCO nod for use of Baricitinib in Covid patients
Natco Pharma has secured emergency use approval for Baricitinib from India’s Central Drugs Standard Control Organization (CDSCO) for the treatment of Covid-19. The Indian pharma ... Read More
Grifols phase 3 Covid-19 trial of hyperimmune globulins fails to meet objective
Spanish pharma company Grifols said that the phase 3 ITAC clinical trial assessing hyperimmune globulins as a treatment for patients hospitalized with Covid-19 has failed ... Read More
Covid-19 phase 3 trial of lenzilumab : Humanigen announces positive interim results
Humanigen said that lenzilumab has delivered a clinically meaningful impact on the recovery of patients hospitalized with Covid-19, as per the interim data of a ... Read More